Home Cart Sign in  
Chemical Structure| 581073-80-5 Chemical Structure| 581073-80-5

Structure of KJ Pyr 9
CAS No.: 581073-80-5

Chemical Structure| 581073-80-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KJ Pyr 9 is a small-molecule inhibitor of MYC. The Kd of KJ Pyr 9 for MYC in vitro is 6.5±1.0 nM, as determined by backscattering interferometry.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KJ Pyr 9

CAS No. :581073-80-5
Formula : C22H15N3O4
M.W : 385.37
SMILES Code : O=C(N)C1=CC=C(C2=CC(C3=CC=CO3)=NC(C4=CC=C([N+]([O-])=O)C=C4)=C2)C=C1
MDL No. :MFCD29081199
InChI Key :GTTDVYCKFQYVNN-UHFFFAOYSA-N
Pubchem ID :85855478

Safety of KJ Pyr 9

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of KJ Pyr 9

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LXF-289 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
BKZ-9 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
BKZ-8 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
BKZ-7 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
BKZ-6 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
BKZ-5 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
BKZ-4 1, 5, 10, 20 µM 5 days Inhibition of the protein–protein interaction of MYC/NMYC with MAX, significantly reducing cell survival Cells. 2021 Apr 27;10(5):1024
RCH-ACV cells 8 μM 60 hours To evaluate the effect of KJ-Pyr-9 on the proliferation and apoptosis of RCH-ACV cells, results showed that KJ-Pyr-9 significantly inhibited cell proliferation and increased apoptosis. Haematologica. 2024 Jul 1;109(7):2092-2110
HEC-59 cells 2.5, 5, 10, 20 μM 72 hours To evaluate the effect of KJ-Pyr-9 on endometrial cancer cell viability, results showed that KJ-Pyr-9 inhibited cell viability in a dose-dependent manner. Cells. 2021 Oct 27;10(11):2916
AN3CA cells 2.5, 5, 10, 20 μM 72 hours To evaluate the effect of KJ-Pyr-9 on endometrial cancer cell viability, results showed that KJ-Pyr-9 inhibited cell viability in a dose-dependent manner. Cells. 2021 Oct 27;10(11):2916
Endometrial carcinoma-derived stem-like cells (ECSCs) 10, 20, 40, 60 µM 120 hours Inhibition of MYC signaling significantly reduced the survival of ECSCs Int J Mol Sci. 2022 Feb 22;23(5):2426
glioblastoma stem cells (GSCs) 40 µM 96 hours Inhibition of MYC/MAX protein-protein interaction, significantly reducing GSC viability to 11.83% Int J Mol Sci. 2022 Oct 26;23(21):12919
malignant mesothelioma cells 12.5 µM 30 hours KJ-Pyr-9 alone or in combination with FRAX597 significantly enhanced apoptosis under serum starvation conditions Am J Cancer Res. 2017 Aug 1;7(8):1724-1737

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish Tg(hsp70:E2A-PBX1-EGFP) transgenic zebrafish Intraperitoneal injection 90 mg/kg For 5 consecutive days To evaluate the effect of KJ-Pyr-9 on hE2A-PBX1-induced AML-like disease in zebrafish, results showed that KJ-Pyr-9 significantly alleviated myeloid cell expansion. Haematologica. 2024 Jul 1;109(7):2092-2110

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.97mL

2.59mL

1.30mL

25.95mL

5.19mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories